LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2028

Conditions

Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaKidney Cancer

Interventions

DRUG

177Lu-PSMA-617

A radioligand therapy, single-dose vial, via intravenous (into the vein) infusion per protocol.

Trial Locations (2)

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston